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Intralesional corticosteroid injection (ICSI) is known as one of the main methods used for treating a wide 
range of lesions. It also results in a high concentration of drugs at lesion sites, with minimal systemic 
absorption. Thus, this study aimed to provide a review of the intralesional corticosteroid injection 
(ICSI) indications in the treatment of oral lesions. To this end; relevant key words were searched in 
the databases of PubMed, Google Scholar, Scopus, ScienceDirect, and UpToDate in the present study. 
Accordingly, the results of a total number of 62 case reports or case series articles were used in this study 
and the positive therapeutic effects of intralesional corticosteroid injection (ICSI) in 23 common oral 
lesions were reported. The most common type of intralesional steroid in the treatment of oral lesions 
was triamcinolone. No significant difference was also observed in terms of pain in patients following 
the use of steroid alone or in combination with anesthetic agents; moreover, the reported side effects of 
this method were exceptionally rare and transient. It was concluded that the intralesional corticosteroid 
injection (ICSI) could be one of the effective therapeutic methods with no significant problems in many 
oral lesions such as inflammatory, immunologic, and vascular ones due to its higher therapeutic effects 
than other topical forms of steroids and fewer side effects than systemic corticosteroid. 
Keywords: Intralesional corticosteroid injection. Triamcinolone. Betamethasone. Oral lesions. Oral 
disorders. Steroid injection.
INTRODUCTION
Intralesional corticosteroid injection (ICSI), 
introduced as a medical treatment in 1951, has become 
one of the main methods used alone or in combination 
with other procedures for treating a wide range of diseases 
as well as benign and malignant proliferations in the head 
and the neck (Egbert et al., 2001; Buckmiller, Francis, 
Galde, 2008; Ffrooz, Tehranchia‐Nia, Ahmed, 1995). 
The ICSI leads to a high concentration of drugs at lesion 
sites, with minimal systemic absorption; therefore, it has 
no common side effects of systemic form or even reduces 
them (Goldman, 1962; Saravanan et al., 2014). However, 
in cases wherein high or repeated doses of injection are 
required, systemic corticosteroid considerations such 
as hypertension, heart failure, uncontrolled diabetes, 
acute peptic ulcer, depression, severe psychosis, and 
active fungal and bacterial infections must be taken 
into account. In addition, the ICSI is preferable to 
the topical corticosteroids such as creams, ointments, 
mouthwashes, gels, and foams due to bypassing of 
mucous membranes, reduced risk of mucosal atrophy, 
higher drug concentrations, and longer durability in 
lesion sites (Laisuan et al., 2017). Nowadays, various 
medications are available for the ICSIs; however, 
physicians commonly prescribe triamcinolone and 
betamethasone derivations. The most important point 
in this therapeutic approach is that the efficacy and the 
potential complications of the injection are dependent 
on its usage method (Ffrooz, Tehranchia‐Nia, Ahmed, 
1995). This injection is performed at offices without 
special supplies and equipment. Prior to injection; the 
history of any allergies, systemic problems, and the use 
of medications such as aspirin and warfarin must be 
taken from patients. Although the local anesthesia can 
be used at the site, it is not usually necessary because 
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the pain created by the ICSI is similar to the injection 
of the anesthetic substance (Saravanan et al., 2014). If 
the injectable material is a suspension, it must be shaken 
well before injection. Corticosteroids, either pure or 
diluted, with saline or anesthetics can be further applied. 
In most oral lesions, 0.1 to 0.2 mL of the substance is 
also injected into four sides of a lesion, and it is normally 
recommended not to increase the total dosage more than 
2 mL in each session. For this purpose, insulin syringe is 
the most suitable injection device. Moreover, the forms 
used for the ICSI do not need to be kept in refrigerator 
thanks to their high shelf life (Richards, 2010). 
Immediate side effects of the injection include 
pain, bleeding, infection, and allergic reaction, as well 
as delayed complications including atrophy of skin or 
mucous membranes, and hyper- or hypo-pigmentation 
of the lesion site (Saravanan et al., 2014; Laisuan et al., 
2017). Although these indications are not very common, 
the possible cause of complications is the lymphogenous 
spread of corticosteroid suspension, which brings 
about dermal and epidermal changes such as thinning 
of the epithelium, loss of rete ridges, necrosis of 
epithelial and small blood vessels, interference with 
synthesis of melanin from melanocytes, reduction of 
mucopolysaccharides, and loss of elastic properties 
of tissues. In this line, the incidence of tissue atrophy 
depends on injection depth and local concentration 
obtained after injection (Hengge et al., 2006; Friedman, 
Butler, Pittelkow, 1988; Schetman, Hambrick, Wilson, 
1963). The ICSI in children can also cause abnormalities 
in their growth and immune system (Buckmiller, Francis, 
& Glade, 2008). Although the occurrence of these 
complications is very rare, it leads to some worries in 
some patients and reduces levels of collaboration in 
treatments. Therefore, the efficacy of this therapeutic 
approach depends on the effective communications 
by physicians with patients along with awareness 
concerning benefits and possible complications (Del 
Rosso, Friedlander, 2005). The ICSI is a safe and cost-
effective process. Accordingly, the employment of this 
method in the treatment of skin lesions has been highly 
reported and approved. Nevertheless, no comprehensive 
review has been so far carried out on applying it in oral 
lesions, administration patterns, drug types and dosages, 
and treatment outcomes. Considering the relatively high 
prevalence rates of oral diseases and the potential of 
benefits of this method, it can be utilized in the treatment 
of numerous oral lesions. Thus, this study aimed to 
present a review of the ICSI indications and treatment 
details in oral lesions to provide more reliable evidence 
for clinicians.
MATERIAL AND METHODS 
The data collection was fulfilled through searching 
in the databases of PubMed, Google Scholar, Scopus, 
ScienceDirect, and UpToDate using relevant keywords 
including corticosteroid injection, intralesional injection, 
triamcinolone injection, betamethasone injection, oral 
lesions, oral disorders, and steroid injection, alone or in 
combination. In this search, no time limit was considered, 
the last access to different platforms was in September 
2018, and the search results were restricted to articles 
published in English. The inclusion criteria for the articles 
composed of: 
1 - Clinical trial articles
2 - Case reports or case series articles 
3 - Treatment of oral lesions or structures related to 
oral cavity; e.g. salivary glands, temporomandibular 
joint, lips, sinuses and oropharynx, no skin, or other 
sites of the body.
4 - Intralesional injection of steroids and no other forms 
of corticosteroids
RESULTS
Following the completion of the search process, 600 
abstracts were obtained and about 200 relevant abstracts 
were reviewed and nearly 80 full-text articles in PDF 
format were selected. In total, 62 articles were included 
in this study. 
DISCUSSION 
The most common causes to use corticosteroid 
drugs in oral medicine are their anti-inflammatory, anti-
proliferative, immunosuppressive, and vasoconstrictive 
effects which appear to be largely mediated by several 
mechanisms such as functioning on stromal capillaries to 
decrease erythema, directing regulation of corticosteroid-
responsive genes by steroid-receptor complex, having 
indirect control over transcription through blockage 
of effects of other transcription factors such as NF-kB, 
inhibiting transcription of various pro-inflammatory 
cytokine genes including interleukin IL-1, IL-2, IL-6, 
interferon gamma (IFN-γ), and tumor necrosis factor-
alpha, stimulating expression of anti-inflammatory 
cytokines genes such as transforming growth factor-B 
and IL-10, making shifts in T-helper type 1 (TH1) to 
TH2 ratio, and decreasing trafficking of lymphocytes 
to lesion sites by diminishing vascular permeability and 
inhibiting proliferation of various cell types including T 
lymphocytes (Norris, 2005). Therefore, steroids are mostly 
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employed in treatment of disorders that are inflammatory, 
hypersensitivity reactions against auto-antigens, as well 
as vascular lesions. It is noteworthy that the ICSI cannot 
alter the nature and the primary mechanisms that lead to 
the disease, but rather have palliative effects and suppress 
the immune system (Saravanan et al., 2014). In this study, 
it was proposed to provide a list of oral lesions that were 
likely to be treated by the ICSI. The details of the treatment 
protocol for each lesion along with treatment results were 
also reported in Table I.
TABLE I - List of articles that applied ICSI to treatment oral lesions




treatment Follow up Side effects
Agha-
Hosseini et al., 
2016
CPLA Triamcinolone 40 mg/mL 3 2 w
Complete 




hemangiomas Triamcinolone and betamethasone 40 and 6 mg/cm
3 1-3 6-25 w (12 w) 11 lesions complete resolution 6 m
4 Patients failure 
to thrive
Meeuwis et al., 
1990 hemangiomas Methylprednisolone 20-40 mg 1-5
Complete 










(instilled through the 
suction drain)
10 mg/kg  
(30-160 mg) 1-2
completely 
disappeared in 1 
case, residual tumor 
excised
1-4 y None
Luo, Gan, 2013 lymphatic malformations
Triamcinolone 
acetonide 
(50 mg/5 mL) + 
Pingyangmycin 
0.625 mg/mL
5 mL 8 2e4 weeks
pingyangmycin 
with triamcinolone 








(0.1 mL with 
0.5 mL of 0.5% 
bupivicaine
6
1 & 2 inj weekly, 
and 4 inj bi-
weekly
90% resolved 10 w None
De La Rosa 
García, 2006 PG Triamcinolone 5 mg 3 - complete resolution - none
Adenis-
Lamarre et al., 
2009
PG Triamcinolone
Dolanmaz et al., 
2016 CGCG
Triamcinolone + 
0.5 % marcaine + 
epinephrine
3.5 mL 6 Weekly
4 complete 
resolution, 2 Partial 
recovery, 1 did not 
response
39 m None
Nogueira et al., 
2010 CGCG
Triamcinolone 
(20 mg/mL) + 
2% lidocaine
0.1 mL/cm3 6 bweekly
15 complete 
resolution, 4 Partial 
recovery, 2 did not 
response
4-8 y None
Sezer et al., 
2005 CGCG
Triamcinolone 
(10 mg/mL) + lidocaine 
2%
4 mL 6 Weekly complete resolution 3 Y None
Da Silva 
Sampieri et al., 
2013




(10 mg/mL, + 
Lidocaine 2% 
orBupivacaine 50%
3-6 mL 4-20 every 15 days- every 3 weeks complete resolution 2-7 y None
Haldar, 1976 Cheilitis glandularis
 Triamcinolone 
1.5 mg/mL
2 to 3 mg in  
10 to 15 Places 10
4 weekly and 
2 biweekly, 
2 monthly, 2 
bimonthly












Twice daily, 2 w
completely 
resolving 1 y None 
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TABLE I - List of articles that applied ICSI to treatment oral lesions (cont.) 




treatment Follow up Side effects
Samiee, 2011 TMD Triamcinolone acetonide, 40 mg/mL 0/5 mL 1 -








0/5-1 mL 1 - reduced signs and symptoms 0.5 - 23 m None
Alstergren et al., 
1996 TMD
methylprednisolone 
40 mg/mL + lidocaine 0/5-0/7 mL 1 -







TMD Betamethasone sodium phosphate+ acetate 0/7-1 mL 2 Biweekly
reduce pain and 
improve function 6 m
Temporary pain 
after injections
Lee et al., 2013 Langerhans cell histiocytosis
methylprednisolone, 
40 mg/mL 3 mL 1 - complete resolution 35 mo None
Milián, 2001 Langerhans cell histiocytosis
Triamcinolone 
acetonide 25 mg 8 every 3 weeks complete resolution 1 y none
Esen et al., 2010 Langerhans cell histiocytosis
methylprednisolone 
succinate (40 mg/mL) 2 mL 3 Every 4 month
Near-complete 
resolution 36 m None





succinate (40 mg/mL) 1-2 mL 1 - complete resolution 9 y None
Graham, Barret, 
Goltz, 1999 Nodular fasciitis
Triamcinolone 
acetonide (10mg/mL) 1.5 mL. 1 - completeresolution 1 y None
Kaplan, 2012 necrotizing sialometaplasia
Dexamethasone+ 
2% lidocaine 10 mg 1 -
The lesion got 
worsen. 1 w None
Keogh et al., 
2004
necrotizing 
sialometaplasia Triamcinolone 10 mg 3 Weekly
There was no 
difference in the rate 
of healing
1 m None





5 mg/mL + 
2 mg/mL 1 -
partial regression 
in first week. No 
recurrence in 6 
months
6 m None
Ohbayashi et al., 
2007 GVHD 0.2% dexamethasone 0.5 mg/cm
2 1 - drastically improving - None
De 





mL (4 case clobetasol 
gel 0.05%
8 to 24 mg 1-9 biweekly drastically improving - None
Villa et al., 2015 mTOR inhibitor stomatitis
Triamcinolone 





2 to 70 days
- None
Xia et al., 2006 Ulcerative OLP Triamcinolone (40 mg/mL 0/5 mL 1 and 2 biweek








0.5 mL 5 4 weekly and 1 biweekly
significantly 
improve in pain and 
burning mouth
1 y cushingoid features.
Liu et al., 2013 OLP Betamethasone Triamcinolone
1.4 mg 
8 mg 2 weekly
Betamethasone 











Metwalli et al., 
2018 OLP
Triamcinolone 








2 case atrophy 
and persistent \ 
erythema
Tilakaratne, 
2016 OSF Methylprednisolone 40 mg 6 monthly
improving mouth 
opening 1 y None
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treatment Follow up Side effects
Singh, 2014 OSF Betamethasone Lycopene 4 mg 16 Twice weekly
Lycopene is better 















Kumar, 2007 OSF Betamethasonee + Lycopene
2 1-mL ampules 
of 4 mg 4 biweekly
Mouth opening was 



































10-15 mg 4 Every three weeks
lesions resolved 
within five to 
sevendays.
18 m None





2g cellcept 10 mg/mL +daily 2
Resolving within 2 
months. 1 year None






40 mg ⁄mL 
diluted 2 : 1 with 
saline (i.e. 




of remission and 
total number of 
corticosteroids
5.3 years Gingival pellets and Candidiasis
Kalinska-
Bienias et al., 
2016
MMP Triamcinolone 0.3 – 2 mL per erosion 2- 18 - remission 6-10 m None
Leroux et al., 
2011 Cluster headache Cortivazol+ verapamil
3.75 mg in 
1.5 mL 3 48-72 hours
Rapidly relief was 
seen in steroid 
group
3-11 m None
Gaul et al., 
2016 Cluster headache
Triamcinolone and 
bupivacaine 10 mg 1 -
Steroid ijectiois 
an easy, safe and 
effective
60 days None
Sinha R, 2016 Mucocele Betamethason4 mg/ mL 1 mL 2-4 weekly
18 case complete 
resolved, 2 case 
Reduced in size
6 m Mild discomfort
Mortazavi et al., 
2017 M ucocele
dexamethasone (8 mg/2 
mL + silk sutures) 3 weekly Complete healing 6 m None
Baharvand 
et al., 2014 Mucocele
8 mg/mL 
Dexamethasone 1 mL 3 weekly
7 case complete 
resolved 2 case 
Reduced in size
(6-20 m) Mild discomfort





40 mg/mL 1 mL (4 mg) 2-3 weekly
lip swellingsettle in 












acetonide - 2 biweekly
Improvement with 
no recurrences 1 y None
van der 









to ICSI. 8.2 y None





acetonide 5.0-4.0 mg/mL 2-4 biweekly
lesions 
healedcompletely - None






(2.5 mg ⁄ mL).
0.1 mL 2 biweekly healedcompletely 1 y None
Kaur et al., 2001 Plasma Cell Cheilitis
triamcinolone 





neuralgia 2 excellent pain relief
TABLE I - List of articles that applied ICSI to treatment oral lesions (cont.) 
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neuralgia Methylprednisolone 40 mg 1 -
Calcitonin was 
better than steroid 2w to 12m None
Hannon, 1983 Foreign-body Granuloma
Triamcinolone 
diacetate
0.7 mL and 0.5 







acetonide 40 mg in 1 mL 4 weekly
completely 
resolved. 7 m none
TABLE I - List of articles that applied ICSI to treatment oral lesions (cont.) 
Caliber-Persistent Labial-Artery (CPLA)
This lesion is an initial arterial branch that, without 
dividing and decreasing the diameter, can penetrate into 
subcutaneous tissue of the lips and create a noticeable 
palpable lesion. In 2016, Agha-Hosseini et al. reported 
a complete improvement of a lesion in the upper lip of 
patients following three triamcinolone injections (Agha‐
Hosseini, Sheykhbahaei, 2016).
Hemangioma
Hemangioma is known t as the most common 
neonatal tumor that occurs at birth or during the first few 
weeks of birth in the head and the neck. The occurrence 
of this lesion in the oral mucosa is relatively rare and can 
affect the lips, cheeks, tongue, gums, mucous membranes, 
jawbones, and salivary glands (Chen, Yeong, & Horng, 
2000; Dilip, Madhukar, & Prithviraj, 2016). Two studies 
in 1990 and 2008 also showed the significant effects 
of the ICSI treatment on parotid gland hemangiomas 
and subglottic hemangiomas (Meeuwis et al., 1990; 
Buckmiller, Francis, & Glade, 2008).
Lymphangioma
Lymphangioma is a developmental tumor of 
the lymphatic origin. Lymphangioma is covered by 
endothelial cells and it often contains high vascular 
contents. Therefore, it can be treated with a similar 
mechanism of hemangioma (Farmand, Kuttenberger, 
1996). A number of reports have been further registered 
on triamcinolone successful injection in the treatment of 
cystic hygroma and vascular malformations of the face and 
the head (Luo, Gan, 2013; Farmand, Kuttenberger, 1996).
Upregulating vasaconstrictor receptors on the 
vascular smooth muscle cells, increased production of 
angiotensin, augmented angiotensin converting enzyme 
(ACE) performance on vascular smooth muscles and 
endothelium, increased protein concentration of signal 
transmission from receptors, strengthened connection of 
signal transmission to receptor, increased intracellular 
vasaconstrictor production such as endothelin and 
decreased intracellular vasodilator production (Agha‐
Hosseini, Sheykhbahaei, 2016), tightened precapillary 
sphincters, and competition for estrogen receptors 
have been the proposed mechanisms for the effects of 
corticosteroids in the improvement of vascular lesions 
(Dilip, Madhukar, Prithviraj, 2016).
Pyogenic Granuloma (PG)
It is a benign, usually single, vascular lesion within 
the mouth that is found most commonly in the gum and 
the upper anterior teeth, but other areas of the mouth, such 
as the lips, tongue, and cheeks may also be involved. In 
this regard, two studies revealed the theraputic effects 
of corticosteroid injection in recurrent PG as well as 
PG in patients with GVHD; respectively (Parisi, Glick, 
Glick, 2006; de la Rosa-Garcia et al., 2006; Adenis-
Lamarre et al., 2009). It seems that both anti-inflammatory 
effects and the above-mentioned mechanisms for the 
improvement of vascular lesions are helpful in improving 
PG.
Central Giant Cell Granuloma (CGCG)
This benign lesion in the jaw is limited to tooth-
bearing areas, which sometimes shows a behavior similar 
to neoplasm (Motamedi et al., 2007). In cases wherein the 
lesion size is large and surgery can lead to functional or 
cosmetic defects and even bleeding during surgery, the 
ICSI can be much more effective. There have been also 
numerous recent reports of the beneficial impacts of the 
ICSI on the treatment of these lesions (Nogueira et al., 
2010; Carlos, Sedano, 2002; Sezer et al., 2005; da Silva 
Sampieri et al., 2013; Dolanmaz et al., 2016). The use 
of the ICSI to treat this lesion was first proposed by 
Jacovay et al. (Rajeevan, Soumithran, 1998). Santos et al., 
in 2018, also reported the treatment of brown tumor 
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associated with hyper-parathyroidism as a lesion which is 
clinicopathologically similar to CGCG (Dos Santos et al., 
2018). Stimulated proliferation and differentiation of 
precursor cells into osteoclasts, inhibited activity of mature 
osteoclast cells, induced apoptosis of osteoclast-like cells, 
and the impeded extracellular production of lyzosomal 
proteases are the proposed mechanisms of the ICSI effect 
in the treatment of CGCG (Nogueira et al., 2010; Carlos, 
Sedano, 2002; da Silva Sampieri et al., 2013). It seems 
that the given method can be also employed to treat similar 
lesions with too much bleeding, such as peripheral giant-
cell granuloma (PGCG) and aneurysmal bone cyst (ABC). 
However, there have been no reports on the efficacy of 
this method in the treatment of these intra-oral lesions, 
although there are few reports about the treatment of ABC 
in other bones using the ICSI (Fraser, Coates, Cole, 1992; 
Gladden Jr et al., 2000).
Glandular Cheilitis (GC)
This is a chronic inflammatory process that involves 
the mucus salivary glands and their ducts which frequently 
occurs in the lower lip of adult males. It is not a naturally 
pre-malignant lesion (Haldar, 1976) and its clinical forms 
are simple, superficial suppurative and deep suppurative 
(Carrington, Horn, 2006). In 1976, complete treatment of 
this lesion was reported by the ICSI method (Haldar, 1976). 
In 2018, Sugaya demonstrated complete improvement of 
GC following two triamcinalone injections and 0.1% 
tacrolimus ointment application (Sugaya, Migliari, 2018). 
Temporomandibular Disorder (TMD)
A group of patients with temporomandibular joint 
disorders experience pain, tenderness, and long-term 
motor limitations despite conservative treatments. In 
these situations, intra-articular corticosteroid injection is 
considered to improve the disease symptoms (Kopp et al., 
1987). In this regard, different studies have examined the 
effects of this method on a variety of subjective symptoms, 
radiographic symptoms, as well as histological changes in 
the articulated tissues (El-Hakim, Abdel-Hamid, Bader, 
2005). The anti-inflammatory effects of corticosteroids 
are also manifested through their effects on the release 
of neuropeptides from the end of neural fibers, inhibitory 
effects on the production of inflammatory mediators such as 
prostaglandin and leukotriene, and corticosteroid through 
the synthesis of lipoprotein as an inhibitory protein on 
phospholipase A2 (Agha‐Hosseini, Sheykhbahaei, 2016; 
Alstergren et al., 1996). The potential side effects of intra-
articular corticosteroid therapy include joint destruction, 
infection, and sometimes disease progression (El-Hakim, 
Abdel-Hamid, Bader, 2005; Kopp et al., 1985). Various 
investigations have further highlighted the benefits of the 
ICSI treatment in a variety of TMDs (Alstergren et al., 
1996; Samiee et al., 2011; Stoll et al., 2012; Bjørnland, 
Gjaerum, Møystad, 2007). 
Granulomatosis disorder
Orofacial granulomatous lesions are uncommon 
chronic conditions with multifactorial etiology and 
unexplained pathogenesis that mostly occur due to 
systemic conditions such as Crohn’s disease, sarcoidosis, 
tuberculosis, or local causes such as chronic infections, 
foreign bodies, and allergies (Ravindran, Karunakaran, 
2013). Clinically, they are usually in the form of a 
persistent or recurrent swelling that affects the lips. In 
addition, conditions such as Melkersson-Rosenthal 
syndrome and Miescher’s cheilitis should be also 
considered among these lesions (Miest, Bruce, Rogers, 
2016). A few recent studies on the positive effects of using 
the ICSI in treating such lesions were mentioned in Table 
(Ravindran, Karunakaran, 2013; Mignogna et al., 2004; 
Van Der Waal et al., 2002).
Plasma-cell cheilitis
This lesion is a benign idiopathic inflammatory 
condition, which is represented by dense infiltration of 
plasma cells in mucous and is usually shown as a plaque 
or patch with an eroded, flattened, or slightly raised and 
round surface. In patients with plasma-cell cheilitis, the 
degree of induced acanthosis in tissue appears to be an 
important factor determining the outcomes of treatment 
by topical corticosteroids (Yang et al., 2005; Tseng et al., 
2009; Kaur et al., 2001).
Lymphoid hyperplasia
The lymphoid hyperplasia lesions are basically a 
propagation of benign lymphocytic reactivity with unclear 
etiology, usually seen as an exophytic mass of soft tissues 
with an intact surface in the areas of the mouth that have 
lymphoid tissues, such as the Waldeyer’s tonsillar ring and 
the lateral border of the tongue and the palate. Follicular 
types are usually the same as the normal mucosal in color 
appearance; otherwise, they may be blue-black or purple-
red. These lesions have been often treated by a surgical 
procedure and through removal of the lesion with many 
complications, especially in the posterior regions of the 
mouth. However, one study in 2013 showed that the ICSI 
N. Gholizadeh, M.-S. Sadrzadeh-Afshar, N. Sheykhbahaei
Braz. J. Pharm. Sci. 2020;56:e18077Page 8 / 15
with the probable mechanism of inductions of apoptosis in 
activated T lymphocytes could easily treat these types of 
lesions with no complications (Anjomshoaa et al., 2013).
Vesiculobullous disorder
Vesiculobullous lesions are a category of chronic 
mucosal ulcers. In this respect, pemphigus vulgaris 
and benign mucous membrane pemphigoid (BMMP) 
is one of the most common lesions in the mouth. The 
primary treatment of these lesions is using the systemic 
corticosteroid, which can be employed in combination 
with immunosuppressive drugs. The ICSI in these lesions 
is not recommended during relapse/flare periods due to 
inadequate effects. It seems that the given method is the 
most effective one in the maintenance phase; as more 
than 70% of the lesions are improved and the systemic 
corticosteroid is getting tapered (Fortuna & Mignogna, 
2011; Mignogna et al., 2010; Nguyen & Ahmed, 2014; 
Abbas et al., 2014; Kalinska‐Bienias et al., 2016). In this 
respect, a study in 2018 demonstrated that the ICSI in 
combination with immunosuppressive drugs could lead 
to reduced dose of corticosteroids and shortened time of 
clinical improvements (Mignogna et al., 2010).
 
Trigeminal neuralgia
Trigeminal neuralgia is known as one of the most 
common causes of facial pains, which usually occurs as 
one-side sudden, severe, pulsating, recurrent, and diffused 
pain in one or more trigeminal branches. The ICSI is one of 
the proposed therapies in this painful disorder particularly 
in the trigger point of pain or involved neural branch 
blocks (Gronseth et al., 2008). There are also contradictory 
reports on the effectiveness of this method (Ebrahimi, 
Nader, Kendall, 2016; Elsheikh, Amr, 2016).
Cluster headache
Cluster headache is one of the most severe and 
debilitating types of primary headaches. Corticosteroid 
injection in the greater occipital nerve is also recognized 
as one of the theraputic options. Some of the reports on 
the positive effects of this treatment were presented in this 
study (Gaul et al., 2016; Leroux et al., 2011). 
Necrotizing sialometaplasia
This is a rare inflammatory disease of the minor 
salivary gland that, in most cases, affects multiple glands 
in the hard palate due to an ischemic event. The lesion 
is self-limiting within 3 to 12 weeks and the supporting 
and symptomatic methods are considered as the basis for 
its treatment. Two studies in 2004 and 2012 showed that 
intralesional triamcinolone had no significant effect on 
the improvement of the lesion and, in some cases; it had 
exacerbated the necrosis (Kaplan et al., 2012; Keogh et al., 
2004). It seems that trauma of drug injection, high doses of 
injectable substance, and lower keratinized tissue nature 
could reduce the acceptability of the substance and lead 
to more necrosis in this site or even no improvements. 
Accordingly, the ICSI was not recommended as a suitable 
method for the treatment of these lesions.
Recurrent Aphthous Stomatitis (RAS)
This is one of the most common oral ulcers with 
an approximate incidence rate of 5-50% (Pakfetrat et al., 
2010). In this respect, the ICSI reduces the symptoms, 
the course of the disease, and the period of normal mucus 
repair; but it does not affect the rate and the frequency of 
its recurrence (Picciani et al., 2010).
The role of the immune system in producing the 
RAS has been largely proven. The reduction in the 
proportion of T helper cells relative to T-cytotoxic cells 
and the special role of some types of human leukocyte 
antigens (HLAs) such as IL-IB and IL-6 have been well-
illustrated. Steroids, through inhibition of lymphocyte 
B and effector T cells, can thus cut the response of 
these cells to accelerators such as allergies, trauma, and 
stress; and ultimately inflammatory processes can have 
palliative effects in improving symptoms in patients 
(Saravanan et al., 2014).
Langerhans Cell Histiocytosis (LCD)
This is a rare disease with unclear etiology, 
characterized by monoclonal proliferation of langerhans 
cells. Some believe that the LCD is a neoplastic process. 
These lesions inside the mouth can also affect soft tissues, 
hard tissues, or both (Esen et al., 2010). Routine treatment 
of this disease is also a major surgery with radiotherapy 
and chemotherapy, although in some cases self-healing 
has been also reported. The beneficial therapeutic benefits 
of the ICSI in the treatment of these lesions have been 
frequently reported (Esen et al., 2010; Putters et al., 
2005; Lee, Yoon, 2013; Merglová et al., 2014). Even 
some studies have regarded it as the first line of treatment 
for the LCD due to fewer invasions as well as easier and 
cheaper prescriptions (Lee & Yoon, 2013). Suppressing 
the langerhans cells, T lymphocytes, eosinophils, and 
osteoclast-like cells are the suggested mechanisms for 
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the effect of this method on the treatment of these lesions 
(Esen et al., 2010).
Nodular fasciitis
This is a benign inflammatory fibroblastic lesion. 
It also has a relatively benign clinical behavior but it is 
similar to sarcoma in terms of histopathologic evaluations. 
Due to the rapid growth and infiltration in the muscles, 
radical surgery approach is needed. In this respect, a study 
(1999) reported the successful treatment of this lesion 
using the ICSI (Graham, Barret, Goltz, 1999). 
Mamelian target of rapamycine inhibitor-
associated stomatitis
Mamelian target of rapamycin (mTOR) is a serine/
threonine kinase that is essential for regulating cell growth 
and proliferation. Inhibition of this enzyme is one of the 
relatively new approaches in cancer management, as a target 
therapy. The side effects of this treatment include stomatitis, 
dermatitis, anorexia, nausea, and vomiting. Stomatitis is 
seen in the form of lesions that are quite similar to the RAS 
in the mouth (de Oliveira et al., 2011). Unlike mucositis 
caused by chemotherapy and radiotherapy, steroids are 
not good treatments for it, so the use of a variety of local, 
intralesional or systemic corticosteroids can be effective in 
the treatment of stomatitis induced by the mTOR inhibitor 
(de Oliveira et al., 2011; Peterson et al., 2016; Villa et al., 
2015), even though some studies have reported self-
improvements without any interventions and treatments 
(Dominguez et al., 2000).
Oral Lichen Planus (OLP)
The OLP is known as one of the most common 
chronic inflammatory lesions within the mouth that can 
also affect skin, nails, hair, and other mucous membranes. 
Oral lesions are more resistant to treatments. In addition, 
lichenoid lesions with similar clinical manifestations can 
be created inside the mouth due to the use of drugs as 
well as contact with restorative or prosthetic materials. 
Regarding the role of immune system and autoreactive 
reactions in the etiopathogenesis of this disease, the use 
of various types of corticosteroids has been accepted as 
the first line treatment of this lesion (Agha-Hosseini et al., 
2016). The use of the ICSI in the treatment of these 
lesions, especially those areas with more inflammations 
and manifestations such as erosion and ulcers, can be 
very effective in controlling the symptoms in patients 
(Lee et al., 2013; Xia et al., 2006; Borahan, Fisekcioglu, 
Alpay, 2014; Liu et al., 2013). The effect of the ICSI in the 
treatment of the OLP in children has been also reported 
with no certain complications (De Moraes et al., 2011). 
In 2018, Metwalli reported the same effects of Bacillus 
Calmette-Guerin polysaccharide nucleic acid extract 
versus triamcinolone acetonide intralesional injection in 
the treatment of OLP (Metwalli et al., 2018). 
Mucocele
Mucocell may occur through extravasation and 
retention phenomena in the salivary glands. Extravasation 
is caused due to salivary glandular duct rupture and 
retention is caused due to dilation of the gland duct. Non-
surgical therapies include cryosurgery, ICSI, sclerosing 
materials, lasers, and micro-crystallization. In this 
respect, corticosteroids seem to result in accumulation and 
contraction of the expanded duct of the salivary glands or 
induction of freezing similar to sclerosing agents (Agha‐
Hosseini, Sheykhbahaei, 2016; Mortazavi et al., 2014; 
Baharvand, Sabounchi, Mortazavi, 2014).
Foreign Body Granuloma
Entrance of any foreign materials into the oral 
mucosa such as suturing, restorative and abrasive 
materials, denture, anesthetic needle, injection of facial 
beauty gels or even bristles of toothbrushes can lead to 
chronic or acute inflammatory infiltration which produce 
granulomatous reactions. In this regard, a number of 
reports have been published about the beneficial effects 
of the ICSI in the treatment of granulomas in the lips 
(Shahrabi-Farahani et al., 2014; Jham et al., 2009). 
Lupus Erythematosus
This is a multi-system inflammatory disease with 
rare oral manifestations (Netto et al., 2017). The oral 
manifestations in these patients can be seen as non-
specific ulcers or white and red plaques with discoid 
manifestations in different oral areas such as palate, 
cheeks, tongue, and gums. Although several studies have 
reported successful treatments of lupus skin lesions using 
the ICSI (Yaşar et al., 2017; Callen, 2006), no report was 
found on the use of oral lesion treatment via this method 
to be reviewed in this study.
Graft-versus-Host Disease (GvHD)
This is one of the main complaints following 
allogeneic transplant of hematopoietic stem cells. More 
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than 80% of cases of this disorder can affect oral mucosa, 
in addition to involvement of several organs. Oral 
symptoms can be also present in acute phases as non-
specific ulcers but they can be similar to OLP, scleroderma, 
Sjögren syndrome, and dysgeusia in chronic phases. 
One of the theraputic options for oral GvHD lesions 
is corticosteroid. In this respect, one study was found 
reporting the use of the ICSI method in the treatment of 
the GvHD (Ohbayashi et al., 2007).
Other Uses
In addition to the above-mentioned applications 
of the ICSI for the treatment of intraoral lesions, 
corticosteroid injection is further employed in other 
dental conditions; e.g., controlling postoperative pain 
and swelling, increasing teeth movements in orthodontic 
treatments, and preventing esophageal stenosis after 
endoscopic dissection and joint stiffness after trauma 
(Zerener et al., 2015; Abtahi et al., 2014; Ohki et al., 2012; 
Efird et al., 2014).
CONCLUSION
The ICSI can be considered as one of the effective 
therapeutic methods with no significant problems in the 
treatment of many oral lesions such as inflammatory, 
immunologic, and vascular disorders. It can also have 
higher therapeutic effects than other topical forms 
of steroids and fewer side effects than systemic 
corticosteroids. According to the results of this study, 
further research studies are recommended to be conducted 
about the effects of this therapeutic approach in many 
common oral lesions.
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